Need professional-grade analysis? Visit stockanalysis.com
$10.79B
35.18
546
N/A
Lepu Biopharma Co Ltd (2157) trades on Hong Kong Stock Exchange in HKD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at HKD6.37, down 2.15% from the previous close.
Over the past year, 2157 has traded between a low of HKD3.96 and a high of HKD10.18. The stock has gained 50.6% over this period. It is currently 37.4% below its 52-week high.
Lepu Biopharma Co Ltd has a market capitalization of $10.79B, with a price-to-earnings ratio of 35.18.
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of first-in class and best-in-class drug candidates in anti-tumor targeted therapy and oncology immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of solid tumors and melanoma. It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; and MRG002, which is in phase III trials to treat breast and urothelial cancer, as well as HER2-positive. In addition, the company is developing MRG001 CD20-targeted ADC for treating non-Hodgkin's lymphoma; CMG901 CLDN18.2-targeted ADC for treating gastric and gastroesophageal junction carcinoma and other solid tumors; and MRG004A TF-targeted ADC for treating advanced or metastatic solid tumors. Further, it is developing CG00705 Oncolytic virus for treating bacillus calmette-guerin unresponsive non-muscle invasive bladder cancer; and MRG006A and CTM012 for the treatment of solid tumors. The company was incorporated in 2018 and is headquartered in Shanghai, China. Lepu Biopharma Co., Ltd. operates as a subsidiary of Ningbo Houde Yimin Information Technology Co., Ltd.
Side-by-side comparison against top Healthcare peers.